guest ::
| Home > Publications database > Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer > print |
| Home > Publications database > Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer > print |
| 001 | 916866 | ||
| 005 | 20230224084253.0 | ||
| 024 | 7 | _ | |a 10.1007/s11307-022-01749-7 |2 doi |
| 024 | 7 | _ | |a 1536-1632 |2 ISSN |
| 024 | 7 | _ | |a 1860-2002 |2 ISSN |
| 024 | 7 | _ | |a 2128/33592 |2 Handle |
| 024 | 7 | _ | |a 35771317 |2 pmid |
| 024 | 7 | _ | |a WOS:000819277600001 |2 WOS |
| 037 | _ | _ | |a FZJ-2023-00158 |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Wegen, Simone |0 P:(DE-HGF)0 |b 0 |e Corresponding author |
| 245 | _ | _ | |a Head-to-Head Comparison of [68 Ga]Ga-FAPI-46-PET/CT and [18F]F-FDG-PET/CT for Radiotherapy Planning in Head and Neck Cancer |
| 260 | _ | _ | |a Cham |c 2022 |b Springer Nature Switzerland |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1673619836_26271 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Introduction: In head and neck cancers (HNCs), fibroblast activation protein (FAP) is expressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment. Preliminary evidence suggests that detection and staging is feasible with positron emission tomography (PET/CT) imaging using [68 Ga]-radiolabeled inhibitors of FAP ([68 Ga]Ga-FAPI-46) in HNCs. This study aims to compare [68 Ga]Ga-FAPI-46 PET/CT and [18F]-fluorodeoxy-D-glucose ([18F]F-FDG) PET/CT with a focus on improved target volume definition and radiotherapy planning in patients with HNC referred for chemoradiation.Methods: A total of 15 patients with HNCs received both [68 Ga]Ga-FAPI-46 PET/CT and [18F]F-FDG PET/CT with a thermoplastic mask, in addition to initial tumor staging by conventional imaging with contrast-enhanced CT and/or MRI. Mean intervals between FAPI/FDG and FAPI/conventional imaging were 4 ± 20 and 17 ± 18 days, respectively. Location and number of suspicious lesions revealed by the different procedures were recorded. Subsequently, expert-generated gross tumor volumes (GTVs) based on conventional imaging were compared to those based on [18F]F-FDG and [68 Ga]Ga-FAPI-46 PET/CT to measure the impact on subsequent radiation planning.Results: All patients had focal FAPI uptake above background in tumor lesions. Compared to FDG, tumor uptake (median SUVmax 10.2 vs. 7.3, p = 0.008) and tumor-to-background ratios were significantly higher with FAPI than with FDG (SUVmean liver: 9.3 vs. 3.2, p < 0.001; SUVmean bloodpool: 6.9 vs. 4.0, p < 0.001). A total of 49 lesions were recorded. Of these, 40 (82%) were FDG+ and 41 (84%) were FAP+. There were 5 (10%) FAP+/FDG- lesions and 4 (8%) FAP-/FDG+ lesions. Volumetrically, a significant difference was found between the GTVs (median 57.9 ml in the FAPI-GTV, 42.5 ml in the FDG-GTV, compared to 39.2 ml in the conventional-GTV). Disease stage identified by FAPI PET/CT was mostly concordant with FDG PET/CT. Compared to conventional imaging, five patients (33%) were upstaged following imaging with FAPI and FDG PET/CT.Conclusion: We demonstrate that [68 Ga]Ga-FAPI-46 -PET/CT is useful for detecting tumor lesions in patients with HNCs. There is now a need for prospective randomized studies to confirm the role of [68 Ga]Ga-FAPI-46 PET/CT in relation to [18F]F-FDG PET/CT in HNCs and to evaluate its impact on clinical outcome.Keywords: FAPI; FDG/PET; Head and neck cancer; PET-based; Radiotherapy planning. |
| 536 | _ | _ | |a 899 - ohne Topic (POF4-899) |0 G:(DE-HGF)POF4-899 |c POF4-899 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a van Heek, Lutz |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Linde, Philipp |0 P:(DE-HGF)0 |b 2 |
| 700 | 1 | _ | |a Claus, Karina |0 P:(DE-HGF)0 |b 3 |
| 700 | 1 | _ | |a Akuamoa-Boateng, Dennis |0 P:(DE-HGF)0 |b 4 |
| 700 | 1 | _ | |a Baues, Christian |0 P:(DE-HGF)0 |b 5 |
| 700 | 1 | _ | |a Sharma, Shachi Jenny |0 P:(DE-HGF)0 |b 6 |
| 700 | 1 | _ | |a Schomäcker, Klaus |0 P:(DE-HGF)0 |b 7 |
| 700 | 1 | _ | |a Fischer, Thomas |0 P:(DE-HGF)0 |b 8 |
| 700 | 1 | _ | |a Roth, Katrin Sabine |0 P:(DE-HGF)0 |b 9 |
| 700 | 1 | _ | |a Klußmann, Jens Peter |0 P:(DE-HGF)0 |b 10 |
| 700 | 1 | _ | |a Marnitz, Simone |0 P:(DE-HGF)0 |b 11 |
| 700 | 1 | _ | |a Drzezga, Alexander |0 P:(DE-Juel1)177611 |b 12 |
| 700 | 1 | _ | |a Kobe, Carsten |0 P:(DE-HGF)0 |b 13 |
| 773 | _ | _ | |a 10.1007/s11307-022-01749-7 |g Vol. 24, no. 6, p. 986 - 994 |0 PERI:(DE-600)2079211-6 |n 6 |p 986 - 994 |t Molecular imaging & biology |v 24 |y 2022 |x 1536-1632 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/916866/files/s11307-022-01749-7.pdf |y OpenAccess |
| 909 | C | O | |o oai:juser.fz-juelich.de:916866 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 12 |6 P:(DE-Juel1)177611 |
| 913 | 1 | _ | |a DE-HGF |b Programmungebundene Forschung |l ohne Programm |1 G:(DE-HGF)POF4-890 |0 G:(DE-HGF)POF4-899 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-800 |4 G:(DE-HGF)POF |v ohne Topic |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-11 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY 4.0 |0 LIC:(DE-HGF)CCBY4 |2 HGFVOC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2022-11-11 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b MOL IMAGING BIOL : 2021 |d 2022-11-11 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-11 |
| 915 | _ | _ | |a DEAL Springer |0 StatID:(DE-HGF)3002 |2 StatID |d 2022-11-11 |w ger |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2022-11-11 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2022-11-11 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2022-11-11 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2022-11-11 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-2-20090406 |k INM-2 |l Molekulare Organisation des Gehirns |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-Juel1)INM-2-20090406 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|